AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 34458731
Drug: Standard care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard care (management of antimicrobial therapy by the treating team)
Trial: 36708956
Drug: Vortioxetine 20
RxNorm normalized name: vortioxetine 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vortioxetine 20 mg/day
Trial: 33454989
Drug: Thyroxine (T4)
DrugBank: Levothyroxine (DB00451)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Thyroxine (T4) and Thyroid-stimulating hormone (TSH)
Trial: 33454989
Drug: Thyroid hormones
RxNorm normalized name: Thyroid hormones
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thyroid hormones (fT4 and TSH)
Trial: 33712267
Drug: Second-line therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Second-line therapy with Gem/NabP or FOLFIRINOX
Trial: 35311753
Drug: Closed-incision negative-pressure
RxNorm normalized name: INCISED NOTOPTERYGIUM RHIZOME OR ROOT (NOTOPTERYGIUM FRANCHETII)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Closed-incision negative-pressure wound therapy for 5 days
Trial: 35311753
Drug: Closed-incision negative-pressure
RxNorm normalized name: INCISED NOTOPTERYGIUM RHIZOME OR ROOT (NOTOPTERYGIUM FRANCHETII)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Closed-incision negative-pressure wound therapy
Trial: 32047245
Drug: 5 g TestimTM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 g TestimTM gel (containing 50 mg testosterone)
Trial: 32892305
Drug: Preferred music
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preferred music therapy (PMT) which included educational counseling (EC) plus 15, 30-min preferred music sessions (PMS)
Trial: 32725584
Drug: Mirabegron 25
RxNorm normalized name: mirabegron 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mirabegron 25 mg/day
Trial: 36069798
Drug: Blended Cognitive
RxNorm normalized name: Io-Blend
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blended Cognitive Behavioral Therapy (B‐CBT) - 6 sessions of face-to-face CBT alternated with 6-8 web-based CBT self-help modules.
Trial: 36069798
Drug: Face-to-Face Cognitive
RxNorm normalized name: FACE SHIELD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Face-to-Face Cognitive Behavioral Therapy (FtF‐CBT) - 12 sessions of traditional face-to-face CBT.
Trial: 36069798
Drug: Blended Cognitive
RxNorm normalized name: Io-Blend
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blended Cognitive Behavioral Therapy (B‐CBT)
Trial: 34111592
Drug: Uva ursi
RxNorm normalized name: UVA URSI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Uva ursi (UU) 105 mg 3 × 2 tablets for 5 days
Trial: 34111592
Drug: Fosfomycin 3-g
RxNorm normalized name: fosfomycin
DrugBank: Fosfomycin (DB00828)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fosfomycin 3-g single dose
Trial: 35567836
Drug: All dosing
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All dosing regimens
Trial: 33221606
Drug: Interpersonal Psychotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interpersonal Psychotherapy (IPT) group treatment for perinatal depression, 12 sessions
Trial: 32328709
Drug: Drospirenone-only pill
RxNorm normalized name: drospirenone Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drospirenone-only pill 4 mg
Trial: 32328709
Drug: Desogestrel 0.075
RxNorm normalized name: desogestrel 0.075 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Desogestrel 0.075 mg
Trial: 35210118
Drug: Intradermal fractional
RxNorm normalized name: plasma protein fraction Injection [Plasmanate]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intradermal fractional third dose of AZD1222 vaccine (20% of standard dose)
Trial: 35210118
Drug: Intradermal fractional
RxNorm normalized name: plasma protein fraction Injection [Plasmanate]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intradermal fractional third dose of AZD1222 vaccine (40% of standard dose)
Trial: 35210118
Drug: Standard intramuscular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard intramuscular third dose of AZD1222 vaccine
Trial: 33788484
Drug: Acupoint electrical
RxNorm normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acupoint electrical stimulation therapy at Huantiao (GB 30), Futu (ST 32), Zusanli (ST 36), Xuanzhong (GB 39), and Taichong (LR 3), 2 times daily for 7 days.
Trial: 33788484
Drug: Routine basic
RxNorm normalized name: Basic Fuchsin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine basic treatment (Control group).
Trial: 33788484
Drug: Acupoint electrical
RxNorm normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acupoint electrical stimulation therapy.
Trial: 34534292
Drug: TS‐161 (15-400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TS‐161 (15-400 mg single dose)
Trial: 34534292
Drug: TS‐161 (50-150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TS‐161 (50-150 mg multiple doses over 10 days)
Trial: 34534292
Drug: TS‐161 (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TS‐161 (100 mg single dose)
Trial: 32771034
Drug: Nigella sativa
RxNorm normalized name: NIGELLA SATIVA SEED
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nigella sativa oil (MARNYS® Cuminmar) 500 mg softgel capsules, one capsule orally twice daily for 10 days plus standard of care treatment (antipyretic, antitussive)
Trial: 38879506
Drug: Standard of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of care treatment
Trial: 33635779
Drug: Choice of
RxNorm normalized name: HYDROGEN PEROXIDE 30 mg in 1 mL TOPICAL LIQUID [MediChoice of Hydrogen Peroxide 3 10 Volume]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Choice of medication reminder modality (text, email, phone)
Trial: 35452419
Drug: Bevacizumab (BVZ)
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bevacizumab (BVZ) plus XELOX chemotherapy with mindfulness-based stress reduction (MBSR) intervention
Trial: 35452419
Drug: XELOX chemotherapy
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: XELOX chemotherapy with conventional care
Trial: 34739648
Drug: Remote Ischaemic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remote Ischaemic Conditioning (RIC) - four 5-min cycles of inflation (20 mmHg above systolic blood pressure) and deflation of an automated blood pressure cuff placed on the upper arm, applied daily for 2 days.
Trial: 34739648
Drug: Sham control
RxNorm normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham control - similar protocol but with low-pressure inflation of 20 mmHg and deflation, applied daily for 2 days.
Trial: 33955942
Drug: Yogic pranayama
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yogic pranayama and diaphragmatic breathing exercises (daily for 6 months)
Trial: 32943015
Drug: Three-monthly multimodal
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three-monthly multimodal vascular risk factor intervention jointly delivered by the trial team and General Practitioner (GP)
Trial: 39118020
Drug: Mandibular implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mandibular implant overdentures
Trial: 33893865
Drug: Er:YAG laser
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Er:YAG laser treatment with meibomian gland expression (MGX)
Trial: 33893865
Drug: MGX-alone treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MGX-alone treatment
Trial: 33893865
Drug: Er:YAG laser
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Er:YAG laser treatment with MGX
Trial: 35084893
Drug: Family-focused therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Family-focused therapy (FFT) for 4 months
Trial: 34530894
Drug: Group-based Problem
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group-based Problem Management Plus (group PM+) with antidepressant therapy (ADT)
Trial: 35690556
Drug: Standard Care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard Care Treatment (SCT)
Trial: 34396571
Drug: 900 µg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 900 µg εPA‐44
Trial: 34396571
Drug: 600 µg
RxNorm normalized name: P.G. 600 KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 µg εPA‐44
Trial: 34653953
Drug: 0.02% HOCl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.02% HOCl nasal spray three times a day for two months
Trial: 33403697
Drug: Intradermal adalimumab
RxNorm normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intradermal adalimumab (40 mg, 0.4 mL)
Trial: 33403697
Drug: Subcutaneous adalimumab
RxNorm normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Subcutaneous adalimumab (40 mg)
Trial: 34621450
Drug: Home Medication
RxNorm normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Home Medication Review by Community Pharmacists (HMR‐CP)
Trial: 35091050
Drug: Quetiapine (400-600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quetiapine (400-600 mg)
Trial: 35091050
Drug: Lithium (1.0-1.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lithium (1.0-1.2 mEq/L)
Trial: 35719216
Drug: Topical lidocaine-prilocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical lidocaine-prilocaine (EMLA®)
Trial: 35373776
Drug: Web-based psychosocial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Web-based psychosocial therapy program via smartphone for 6 weeks
Trial: 33950184
Drug: Home-delivered pill
RxNorm normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Home-delivered pill packs in prepackaged blisters
Trial: 33950184
Drug: Routine pharmacy
RxNorm normalized name: miconazole
DrugBank: Miconazole (DB01110)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Routine pharmacy prescriptions (Control)
Trial: 32840201
Drug: Silver-impregnated ceramic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Silver-impregnated ceramic tablet
Trial: 35717048
Drug: Risk-adapted intraoperative
RxNorm normalized name: ADAPT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risk-adapted intraoperative radiation therapy (IORT)
Trial: 35717048
Drug: External beam
RxNorm normalized name: Beam
DrugBank: Tricyclazole (DB02891)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: External beam radiation therapy (control)
Trial: 32348638
Drug: Inhaled steroids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled steroids (IS) before weaning
Trial: 32348638
Drug: Inhaled steroids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled steroids (IS) after weaning
Trial: 32348638
Drug: No inhaled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No inhaled steroids (IS)
Trial: 34910554
Drug: Genomically directed
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Genomically directed therapy (arm A)
Trial: 34910554
Drug: Treatment of
RxNorm normalized name: DRUGS FOR TREATMENT OF LEPRA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment of physician choice (TPC) (arm B)
Trial: 32060099
Drug: High-dose icotinib
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose icotinib (250 mg, thrice daily; L858R-HD)
Trial: 32060099
Drug: Routine-dose icotinib
RxNorm normalized name: nicotine Metered Dose Nasal Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine-dose icotinib (125 mg, thrice daily; L858R-RD)
Trial: 32060099
Drug: Routine-dose icotinib
RxNorm normalized name: nicotine Metered Dose Nasal Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine-dose icotinib (125 mg, thrice daily; 19-Del-RD)
Trial: 32060099
Drug: High-dose icotinib
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose icotinib (L858R-HD)
Trial: 32060099
Drug: Routine-dose icotinib
RxNorm normalized name: nicotine Metered Dose Nasal Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine-dose icotinib (L858R-RD)
Trial: 32060099
Drug: Routine-dose icotinib
RxNorm normalized name: nicotine Metered Dose Nasal Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine-dose icotinib (19-Del-RD)
Trial: 36322937
Drug: Low-dose hydroxyurea
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose hydroxyurea (10 mg/kg per day)
Trial: 36322937
Drug: Moderate-dose hydroxyurea
RxNorm normalized name: Hydroxyurea
DrugBank: Hydroxyurea (DB01005)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderate-dose hydroxyurea (20 mg/kg per day)
Trial: 32892320
Drug: Spirulina (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spirulina (6 g/day for 7 days)
Trial: 32745555
Drug: Retreatment with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Retreatment with immunosuppressive therapy
Trial: 33471029
Drug: Systematic echocardiographic
RxNorm normalized name: Integrase Inhibitors, antiinfectives for systematic use
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systematic echocardiographic screening followed by secondary antibiotic prophylaxis
Trial: 32213659
Drug: Testosterone replacement
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Testosterone replacement therapy (TRT) - Testosterone undecanoate injection three times/6 months (n = 20)
Trial: 34653515
Drug: Peanut Epicutaneous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peanut Epicutaneous Immunotherapy (49 participants)
Trial: 34653515
Drug: Egg Oral
RxNorm normalized name: Egg Oral Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Egg Oral Immunotherapy or Baked Egg Diet (92 participants)
Trial: 34464306
Drug: levobupivacaine 0.5
RxNorm normalized name: levobupivacaine 0.5 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: levobupivacaine 0.5 mg/kg plus 1?g/kg dexmedetomidine and 0.9% isotonic (Group 4)
Trial: 34464306
Drug: levobupivacaine 0.5
RxNorm normalized name: levobupivacaine 0.5 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: levobupivacaine 0.5 mg/kg plus 0.9% isotonic (Group 2)
Trial: 34464306
Drug: 1?g/kg dexmedetomidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1?g/kg dexmedetomidine plus 0.9% isotonic (Group 3)
Trial: 34464306
Drug: 0.9% isotonic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9% isotonic 20 ml (Group 1)
Trial: 34893026
Drug: General anesthesia
RxNorm normalized name: Ethers for general anesthesia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: General anesthesia with patient-controlled intravenous analgesia (PCIA)
Trial: 33808849
Drug: Traditional Thai
RxNorm normalized name: Thai galangal extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional Thai Massage (TTM) - six weekly 1‐h sessions
Trial: 32458080
Drug: Combined 308-nm
RxNorm normalized name: NM-004
DrugBank: NM-004 (DB18066)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined 308-nm excimer lamp and topical mometasone furoate cream
Trial: 32458080
Drug: 308-nm excimer
RxNorm normalized name: NM-004
DrugBank: NM-004 (DB18066)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 308-nm excimer lamp alone (monotherapy)
Trial: 36454561
Drug: BRIGHT (tele-cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BRIGHT (tele-cognitive behavioral therapy)
Trial: 32271671
Drug: Endocrine therapy
RxNorm normalized name: ENDOCRINE THERAPY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endocrine therapy alone (E)
Trial: 35416182
Drug: 3 g
RxNorm normalized name: Molds 3 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 g each fish and soybean oil daily for 6 weeks
Trial: 32739509
Drug: Sulodexide (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulodexide (oral dose twice a day for 7 days before sclerotherapy, continued for 3 months)
Trial: 32739509
Drug: Standard sclerotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard sclerotherapy protocol (Polidocanol as sclerosing agent, 20 to 30 mm Hg compression stockings for 7 days)
Trial: 39696609
Drug: Oral PrEP
RxNorm normalized name: Iron bivalent, oral preparations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral PrEP
Trial: 32478030
Drug: Video treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Video treatment group (watching a 5-min video about the possible health hazards of MP use)
Trial: 36064731
Drug: Immediate group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate group with access to the wristband solution and standard care
Trial: 32960242
Drug: Prophylactic negative
RxNorm normalized name: polylactic acid-polyglycolic acid copolymer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic negative pressure wound therapy (n = 816, median duration 4 days)
Trial: 35677636
Drug: Compound lactic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Compound lactic acid bacteria capsules combined with escitalopram
Trial: 35465007
Drug: Dexmedetomidine (0.2‐0.7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine (0.2‐0.7 μg/kg/h)
Trial: 32532601
Drug: Individualized homoeopathic
RxNorm normalized name: Urtica urens homeopathic preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individualized homoeopathic treatment (11 medicines prescribed in potencies from 6C to 1M)
Trial: 34687634
Drug: Losartan 100
RxNorm normalized name: LOSARTAN 100MG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Losartan 100 mg daily for 12 months
Trial: 33301009
Drug: 3.3 mL/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3.3 mL/kg of concentrated beetroot juice containing 200 µmol/kg of nitrate
Trial: 33301009
Drug: 3.3 mL/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3.3 mL/kg of concentrated beetroot juice containing 400 µmol/kg of nitrate
Trial: 33301009
Drug: Higher dose
RxNorm normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher dose of nitrate
Trial: 35643988
Drug: Three treatments
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three treatments with CPM‐HA20G (total 3 ml per side)
Trial: 35643988
Drug: One treatment
RxNorm normalized name: Gel-One
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One treatment with CPM‐HA20G (total 1.5 ml per side)
Trial: 33745609
Drug: Magnesium supplementation
RxNorm normalized name: Magnesium
DrugBank: Magnesium (DB14513)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Magnesium supplementation (500 mg daily for 8 weeks)
Trial: 33044240
Drug: Antifungal drugs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antifungal drugs in high-risk critically ill patients without microbiologic documentation of Candida infection
Trial: 33044240
Drug: Higher doses
RxNorm normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher doses of echinocandins for treating invasive candidiasis
Trial: 33044240
Drug: Use of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Use of fungal biomarkers for early initiation or interruption of antifungal therapy
Trial: 34560265
Drug: SaMBA-COPD intervention
RxNorm normalized name: Jasminum sambac flower extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SaMBA-COPD intervention with lay health coaches, including referral to a pharmacist for antibiotic and oral steroid rescue packs and support for a structured home exercise routine.
Trial: 33637618
Drug: Intravitreal injection
RxNorm normalized name: Eylea 2 MG per 0.05 ML Intravitreal Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal injection of conbercept (0.25 mg)
Trial: 33637618
Drug: Intravitreal injection
RxNorm normalized name: Eylea 2 MG per 0.05 ML Intravitreal Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal injection of ranibizumab (0.25 mg)
Trial: 34540595
Drug: Internet-based self-help
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internet-based self-help intervention (8 modules based on cognitive behavioral therapy)
Trial: 33361317
Drug: Control (0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (0 g/day)
Trial: 35758093
Drug: 100 mg/day
RxNorm normalized name: infigratinib phosphate 100 mg/day (100 mg x 1) ORAL CAPSULE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg/day aspirin (ASA)
Trial: 32345787
Drug: Vaginal CO2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaginal CO2 laser treatment
Trial: 33970455
Drug: Centhaquine (0.01
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Centhaquine (0.01 mg/kg in 100 ml normal saline infusion over 1 h)
Trial: 33970455
Drug: Control (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (100 ml normal saline infusion over 1 h)
Trial: 33931900
Drug: Gliadin-protected SOD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gliadin-protected SOD (GP-SOD; 1 g/day for 12 weeks followed by 0.5 g/day for 12 weeks) + NB-UVB
Trial: 32065006
Drug: THC:CBD oromucosal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: THC:CBD oromucosal spray (nabiximols)
Trial: 35723751
Drug: Calcium hydroxide
RxNorm normalized name: Calcium Hydroxide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium hydroxide + 2% chlorhexidine-gel (Ca(OH)2 + 2% CHX-gel)
Trial: 35723751
Drug: Calcium hydroxide
RxNorm normalized name: Calcium Hydroxide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium hydroxide + saline solution (Ca(OH)2 + SSL)
Trial: 35395555
Drug: Soy nut
RxNorm normalized name: soy acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soy nut consumption (67 g/day providing 25.5 g protein and 174 mg isoflavones)
Trial: 35395555
Drug: Soy nut
RxNorm normalized name: soy acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soy nut consumption (67 g/day)
Trial: 34517775
Drug: Polypharmacy (taking
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polypharmacy (taking ?5 medications)